Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany

Applied Health Economics and Health Policy

Volumn 14, Issue 6, 2016, Pages 691-701

  Hofer, Florian ^a   Achelrod, Dmitrij ^a   Stargardt, Tom ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DISEASE SEVERITY; GERMANY; HUMAN; MARKOV CHAIN; META ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TELEMONITORING; AMBULATORY MONITORING; COMPLICATION; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMIC MODEL; ECONOMICS; HOSPITALIZATION; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TELEMEDICINE;

COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE PROGRESSION; GERMANY; HOSPITALIZATION; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONITORING, AMBULATORY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TELEMEDICINE;

EID: 84979987478     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-016-0267-9     Document Type: Article

References (56)

1. Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, et al. The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study. Dtsch Med Wochenschr 1946. 2008;133:2609–14.
2. WHO | Burden of COPD [Internet]. Available from: http://www.who.int/respiratory/copd/burden/en/. Cited 21 Jun 2016.
3. Busse R, Stargardt T, Schreyögg J. Determining the “health benefit basket” of the statutory health insurance scheme in Germany. Eur J Health Econ. 2005;6:30–6.
4. Bayerische TelemedAllianz | Angewandte Telemedizin—Bayerische Projekte, Prävention—Modellvorhaben Telemedizin bei COPD [Internet]. Available from: http://www.telemedallianz.de/at_p_modell_copd.html. Cited 21 Jun 2016.
5. E-Health: Individuelle telemedizinische Betreuung von COPD-Patienten [Internet]. Available from: http://www.philips.de/a-w/about/news/archive/standard/news/healthcare/20150401_Philips_E-Health_Motiva.html. Cited 21 Jun 2016.
6. Henderson C, Knapp M, Fernández J-L, Beecham J, Hirani SP, Cartwright M, et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. BMJ. 2013;346:f1035.
7. Haesum LK, Soerensen N, Dinesen B, Nielsen C, Grann O, Hejlesen O, et al. Cost-utility analysis of a telerehabilitation program: a case study of COPD patients. Telemed E Health. 2012;18:688–92.
8. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. CHEST J. 2007;132:1748–55.
9. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. CHEST J. 2000;117:398S–401S.
10. Van Der Heijden M, Lijnse B, Lucas PJ, Heijdra YF, Schermer TR. Managing COPD exacerbations with telemedicine. Artif Intell Med [Internet]. 2011:169–78. Available from: http://link.springer.com/10.1007%2F978-3-642-22218-4_21. Cited 29 Feb 2016 (Springer).
11. iqwig.de—IQWiG publishes new version of its General Methods [Internet]. Available from: https://www.iqwig.de/en/press/pressemitteilungen/press-releases/iqwig-publishes-new-version-of-its-general-methods.5346.html. Cited 21 Jun 2016.
12. Menn P. Einsatz entscheidungsanalytischer Modelle für die ökonomische Evaluation medizinischer Verfahren am Beispiel chronisch obstruktiver Lungenerkrankungen [Internet]. lmu; 2009. Available from: https://edoc.ub.uni-muenchen.de/10315/. Cited 21 Mar 2016.
13. Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011;14:1039–47.
14. Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011;105:1635–47.
15. Global strategy for diagnosis, management, and prevention of COPD—2016—Global initiative for chronic obstructive lung disease—GOLD [Internet]. Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Cited 21 Jun 2016.
16. Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making. 2008;28:706–12.
17. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
18. Vogelmeier C, Buhl R, Criee CP, Gillissen A, Kardos P, Köhler D, et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie. 2007;61:e1–40.
19. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundbäck B, Donaldson GC, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7:153–67.
20. Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health J Int Soc Pharmacoecon Outcomes Res. 2012;15:796–803.
21. Behandlung: COPD—Onmeda: Medizin and Gesundheit [Internet]. Available from: http://www.onmeda.de/Anwendungsgebiet/COPD.html. Cited 21 Jun 2016.
22. KBV—Online-version des EBM [Internet]. Available from: http://www.kbv.de/html/online-ebm.php. Cited 21 Jun 2016.
23. Report-Browser 2013/2015, InEK GmbH [Internet]. Available from: http://www.g-drg.de/cms/G-DRG-System_2015/Abschlussbericht_zur_Weiterentwicklung_des_G-DRG-Systems_und_Report_Browser/Report-Browser_2013_2015. Cited 21 Jun 2016.
24. Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A, Balbi B, et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009;33:411–8.
25. Upatising B, Wood DL, Kremers WK, Christ SL, Yih Y, Hanson GJ, et al. Cost comparison between home telemonitoring and usual care of older adults: a randomized trial (Tele-ERA). Telemed E Health. 2015;21:3–8.
26. Udsen FW, Hejlesen O, Ehlers LH. A systematic review of the cost and cost-effectiveness of telehealth for patients suffering from chronic obstructive pulmonary disease. J Telemed Telecare. 2015;21:108–18.
27. Maiolo C, Mohamed EI, Fiorani CM, De Lorenzo A. Home telemonitoring for patients with severe respiratory illness: the Italian experience. J Telemed Telecare. 2003;9:67–71.
28. Paré G, Sicotte C, St.-Jules D, Gauthier R. Cost-minimization analysis of a telehomecare program for patients with chronic obstructive pulmonary disease. Telemed J E Health. 2006;12:114–21.
29. Pinnock H, Hanley J, McCloughan L, Todd A, Krishan A, Lewis S, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347:f6070.
30. Trappenburg JC, Niesink A, de Weert-van Oene GH, van der Zeijden H, van Snippenburg R, Peters A, et al. Effects of telemonitoring in patients with chronic obstructive pulmonary disease. Telemed E Health. 2008;14:138–46.
31. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernández C, Alonso A, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J. 2006;28:123–30.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
33. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105:57–66.
34. Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14:354–60.
35. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation [Internet]. OUP Oxford; 2006. Available from: https://books.google.de/books?hl=de&lr=&id=NuYRBAAAQBAJ&oi=fnd&pg=PP1&dq=Decision+modelling+for+health+economic+evaluation&ots=JJR9ZTPCnm&sig=WF76M54HOMPdsWMvw-qISgs29Uk. Cited 21 Jun 2016.
36. Guide to the methods of technology appraisal 2013 | Foreword | Guidance and guidelines | NICE [Internet]. Available from: https://www.nice.org.uk/article/pmg9/chapter/Foreword. Cited 22 Jun 2016.
37. Ahlert M, Breyer F, Schwettmann L. How you ask is what you get: framing effects in willingness-to-pay for a QALY. Soc Sci Med. 2016;150:40–8.
38. WHO | Table: Threshold values for intervention cost-effectiveness by region [Internet]. Available from: http://www.who.int/choice/costs/CER_levels/en/. Cited 21 Jun 2016.
39. Länder and Regionen—Internationales—Daten nach Thema—Basistabelle—Statistisches Bundesamt (Destatis) [Internet]. Available from: https://www.destatis.de/DE/ZahlenFakten/LaenderRegionen/Internationales/Thema/Tabellen/Basistabelle_BIPproKopf.html. Cited 21 Jun 2016.
40. Bartoli L, Zanaboni P, Masella C, Ursini N. Systematic review of telemedicine services for patients affected by chronic obstructive pulmonary disease (COPD). Telemed E Health. 2009;15:877–83.
41. Müller A, Schweizer J, Helms TM, Oeff M, Sprenger C, Zugck C. Telemedical support in patients with chronic heart failure: experience from different projects in Germany. Int J Telemed Appl. 2010;2010:8.
42. Jordan R, Adab P, Jolly K, et al. Telemonitoring for patients with COPD. BMJ [Internet]. 2013;347. Available from: http://www.bmj.com/content/347/bmj.f5932.abstract. Cited 12 Jun 2016.
43. Cruz J, Brooks D, Marques A. Home telemonitoring in COPD: a systematic review of methodologies and patients’ adherence. Int J Med Inf. 2014;83:249–63.
44. Gorst SL, Armitage CJ, Brownsell S, Hawley MS. Home telehealth uptake and continued use among heart failure and chronic obstructive pulmonary disease patients: a systematic review. Ann Behav Med. 2014;48:323–36.
45. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22.
46. Shrier I, Boivin J-F, Steele RJ, Platt RW, Furlan A, Kakuma R, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166:1203–9.
47. Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson S-A, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health J Int Soc Pharmacoecon Outcomes Res. 2014;17:525–36.
48. Zanaboni P, Lien LA, Hjalmarsen A, Wootton R. Long-term telerehabilitation of COPD patients in their homes: interim results from a pilot study in Northern Norway. J Telemed Telecare. 2013;19:425–9.
49. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–50.
50. Peytremann-Bridevaux I, Staeger P, Bridevaux P-O, Ghali WA, Burnand B. Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review and meta-analysis. Am J Med. 2008;121:433–43.
51. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34:634–40.
52. Namensartikel Bundesgesundheitsminister Gröhe—Bundesgesundheitsministerium [Internet]. Available from: http://www.bmg.bund.de/themen/krankenversicherung/e-health-initiative-und-telemedizin/namensartikel-bundesgesundheitsminister-groehe.html. Cited 21 Jun 2016.
53. koordinierte Bevölkerungsvorausberechnung [Internet]. Available from: https://www.destatis.de/bevoelkerungspyramide/#!y=2015. Cited 21 Jun 2016.
54. Lundbäck B, Eriksson B, Lindberg A, Ekerljung L, Muellerova H, Larsson L-G, et al. A 20-year follow-up of a population study-based COPD cohort-report from the obstructive lung disease in Northern Sweden studies. COPD J Chronic Obstr Pulm Dis. 2009;6:263–71.
55. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:1.
56. Leivseth L, Brumpton BM, Nilsen TIL, Mai X-M, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013;68:914–21.